496 related articles for article (PubMed ID: 23838432)
1. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
3. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
4. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
5. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
6. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
7. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
8. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
9. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
10. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
Kanda T; Uchida S
Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
[TBL] [Abstract][Full Text] [Related]
11. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Müller T
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
[TBL] [Abstract][Full Text] [Related]
12. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Carta M; Carlsson T; Kirik D; Björklund A
Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
14. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
[TBL] [Abstract][Full Text] [Related]
15. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
[TBL] [Abstract][Full Text] [Related]
16. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
19. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
